A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

Inclusion Criteria:

• Signed and dated written informed consent in accordance with ICH-GCP and locallegislation prior to admission to the trial

• Male or female who is ≥ 18 (or who is of legal age in countries where that isgreater than 18) and ≤ 75 years old at screening (Visit 1a)

• Clinical signs of Clinically Significant Portal Hypertension (CSPH) as described byeither one of the points below. Each trial patient must have a gastroscopy duringthe screening period (Visit 1b) or within 6 months prior to screening (Visit 1b).

• documented endoscopic proof of oesophageal varices and / or gastric varices atscreening (Visit 1b) or within 6 months prior to screening (Visit 1b)

• documented endoscopic-treated oesophageal varices as preventative treatment

• CSPH defined as baseline Hepatic Venous Pressure Gradient (HVPG) ≥ 10 mmHg (measuredat Visit 1c), based on a local interpretation of the pressure tracing

• Diagnosis of compensated cirrhosis due to Hepatitis C virus (HCV), Hepatitis B virus (HBV), or Non-Alcoholic Steatohepatitis (NASH) with or without Type 2 DiabetesMelitus (T2DM). Diagnosis of cirrhosis must be based on histology (historical datais acceptable) or on clinical evidence of cirrhosis (e.g. platelet count < 150 x 109/L [150 x 103/microlitre (μL)], nodular liver surface on imaging or splenomegalyetc.) Diagnosis of NASH based on either i. Current or historic histologicaldiagnosis of NASH OR steatosis OR ii. Clinical diagnosis of NASH based on historicor current imaging diagnosis of fatty liver (Fibroscan, Ultrasound (US), MagneticResonance Imaging (MRI), Computed Tomography (CT)) AND at least 2 current orhistoric comorbidities of the metabolic syndrome (overweight/obesity, T2DM,hypertension, hyperlipidemia)

• Willing and able to undergo HVPG measurements per protocol (based on Investigatorjudgement)

• If receiving statins must be on a stable dose for at least 3 months prior toscreening (Visit 1b), with no planned dose change throughout the trial

• If receiving treatment with Non-Selective Beta-Blocker (NSBBs) or carvedilol must beon a stable dose for at least 1 months prior to screening (Visit 1b), with noplanned dose change throughout the trial

• Further inclusion criteria apply

Exclusion Criteria:

• Previous clinically significant decompensation events (e.g. ascites [more thanperihepatic ascites], Variceal Haemorrhage (VH) and / or overt / apparent HepaticEncephalopathy (HE))

• History of other forms of chronic liver disease (e.g. alcohol-related liver disease (ARLD), autoimmune liver disease, primary biliary sclerosis, primary sclerosingcholangitis, Wilson's disease, haemachromatosis, alpha-1 antitrypsin [A1At]deficiency)

• Patients without adequate treatment for HBV, HCV or NASH as per local guidance (e.g.antiviral therapy for chronic HBV or HCV infection or lifestyle modification inNASH)

• if received curative anti-viral therapy for HCV, no sustained virologicalresponse (SVR) or SVR sustained for less than 2 years prior to screening or ifHCV Ribonucleic Acid (RNA) detectable

• If receiving anti-viral therapy for HBV, less than 6 months on a stable doseprior to screening, with planned dose change during the trial or HBVdeoxyribonucleic acid (DNA) detectable

• Weight change ≥ 5% within 6 months prior screening

• Must take, or wishes to continue the intake of, restricted concomitant therapy orany concomitant therapy considered likely (based on Investigator judgement) tointerfere with the safe conduct of the trial

• Systolic Blood Pressure (SBP) < 100 mmHg and Diastolic Blood Pressure (DBP) < 70mmHg at screening (Visit 1a)

• Model of End-stage Liver Disease (MELD) score of > 15 at screening (Visit 1a),calculated by the central laboratory

• Hepatic impairment defined as a Child-Turcotte-Pugh score ≥ B8 at screening (Visit 1a), calculated by the site, using central laboratory results

• Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) > 5 times upperlimit of normal (ULN) at screening (Visit 1a), measured by the central laboratory

• Further exclusion criteria apply